Specification:

Description:

Selank is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analogue of a human tetrapeptide tuftsin.
Selank is a synthetic analogue of the immunomodulatory peptide tuftsin; as such, it mimics many of its effects. It has been shown to modulate the expression of Interleukin-6 (IL-6) and affect the balance of T helper cell cytokines. It has been shown to influence the concentration of monoamine neurotransmitters and induce metabolism of serotonin. There is evidence that it may also modulate the expression of brain-derived neurotropic factor (BDNF) in rats.
Selank, as well as a related peptide drug, semax, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, and this action may be involved in their effects.

Application:
Selank is a synthetic derivative of the human body's naturally produced tetrapeptide Tuftsin. It is a hexapeptide whith a wide range of uses. It was first sinthesized in the late 1990's by the Institute of Molecular Genetics of the Russian Academy of Science. Selank is used as an anxiolytic in the therapy of anxiety and phobic disorders, including generalized anxiety. Its action is similar to that of mild benzodiazepins but without the sedative effects. As a selective anxiolytic with a nootropic component, Selank can be used as treatment of depression, fear and general anxiety. It also reduces phsychic tension. This neuropeptide has passed all phases of clinical trials and is now being prepared for registration and mass production.